What's Behind Myriad Genetics' Disastrous Q1 Performance

It's been feast or famine for Myriad Genetics (NASDAQ: MYGN) this year. The stock has skyrocketed more than 50% in a single day. And it has dropped by nearly that much in one day as well.

The genetic testing company announced its fiscal 2020 first-quarter results after the market closed on Monday. And it looks like there will be another famine. Here are the highlights from Myriad's first-quarter update.

Test tubes with images of a DNA helix in one of the test tubes.

Image source: Getty Images.

By the numbers

Myriad Genetics reported revenue of $186.3 million in the first quarter. This reflected an 8% decline from the prior-year period revenue of $202.3 million. The consensus analysts' estimate projected Q1 revenue of $202.1 million.

The company announced a net loss in the first quarter of $20.6 million, or $0.28 per share, based on generally accepted accounting principles (GAAP). This was significantly worse than Myriad's GAAP net loss of $700,000, or $0.01 per share, in the same quarter last year.

Myriad posted non-GAAP (adjusted) earnings of $0.08 per share, down 81% from earnings of $0.43 per share in the prior-year period. This came in well below the average analysts' adjusted earnings estimate of $0.32 per share.

Behind the numbers

CEO Mark C. Capone acknowledged that Myriad "had a challenging start to fiscal year 2020." He stated that the "deletion of the historical hereditary cancer CPT [current procedural terminology] codes" made a big impact on Myriad's hereditary cancer revenue accrual. Hereditary cancer revenue fell 10% from the prior-year period to $104.5 million.

That wasn't Myriad's only problem, though. Sales for the company's GeneSight gene test for antidepressants sank 22% year over year to $22.7 million. Revenue from Myriad's Vectra diagnostic test for rheumatoid arthritis also fell 15% lower to $11 million.

The only bright spot in the company's Q1 results was its prenatal genetic testing. Prenatal revenue jumped 30% year over year to $23.5 million.

Myriad's operating expenses rose 3% from the prior-year period to $207.2 million. This higher spending combined with the revenue shortfall resulted in the company's dismal bottom line.

Looking ahead

Myriad expects that revenue for full-year 2020 will be between $800 million and $810 million. The company anticipates a GAAP loss of between $0.25 and $0.15 per share. Adjusted non-GAAP earnings per share are expected to come in between $1.00 and $1.10.

For the second quarter, Myriad is looking for revenue between $210 million and $212 million. The company projects GAAP earnings per share between $0.00 and a $0.02 loss. Myriad also anticipates non-GAAP adjusted earnings per share in Q2 between $0.30 and $0.32.

Myriad definitely got off to a bad start in fiscal 2020. However, Capone said, "Despite this setback, we expect earnings to be significantly higher in the second half of the fiscal year and believe that a number of important upsides will materialize during the fiscal year generating momentum as we transition into fiscal year 2021."

It's always good to have a long-term perspective when investing in stocks. That's especially the case for Myriad Genetics as its current famine begins.

10 stocks we like better than Myriad Genetics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Myriad Genetics wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks


*Stock Advisor returns as of June 1, 2019


Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More